In Biopharma M&A, 'Where There's Real Innovation There's Someone Willing to Pay'
Deals in biopharma slowed in 2017 for the third consecutive year. According to Intec Pharma CEO Jeffrey Meckler, just because volume is down doesn't mean it's out.
In 2017, deal volume in the biopharma space slowed for the third consecutive year. Value in all of the pharma and life sciences sector totaled only about $181 billion, down 23% from a year earlier, according to PricewaterhouseCoopers.
But according to Intec Pharma Ltd. (NTEC) - Get Report Chief Executive Officer and Vice Chairman Jeffrey Meckler, a slowdown one year doesn't necessarily portend a slowdown the next year. Rather, innovation is often what drives mergers and acquisitions in biopharma.
"Where there's real innovation, there's always someone willing to pay for it," Meckler said.
